World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
154
Citations
112970
World Ranking
989
National Ranking
565

Research.com Recognitions

  • 2007 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John C. Byrd is affiliated with the University of Cincinnati in the United States and has contributed extensively to the fields of Medicine, Biochemistry, Genetics, and Molecular Biology. Their research covers subfields including Pathology and Forensic Medicine, Genetics, Molecular Biology, Oncology, and Hematology.

The scientist's main research topics include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Sphingolipid Metabolism and Signaling
  • Pharmacological Effects of Natural Compounds
  • Drug Transport and Resistance Mechanisms
  • Lung Cancer Treatments and Mutations

John C. Byrd has published research in various venues, contributing multiple papers to the following publication sources:

  • UNC Libraries
  • Hematological Oncology
  • The AAPS Journal
  • Blood
  • Clinical Epigenetics

Notable recent papers by this researcher include:

  • Genetic heterogeneity of diffuse large B-cell lymphoma (2020), published in UNC Libraries
  • Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia (2024), published in Hematological Oncology
  • Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats (2020), published in The AAPS Journal
  • Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies (2024), published in Blood
  • Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 (2020), published in UNC Libraries

The researcher collaborates frequently with several colleagues, including:

  • David A. Rizzieri
  • Kathleen A. Burke
  • Brian Dougherty
  • Veerendra Munugalavadla
  • Richard R. Furman

Among professional recognitions, John C. Byrd was named a Fellow of the American Association for the Advancement of Science (AAAS) in 2007 and holds membership in the Association of American Physicians.

Best Publications

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

    Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon

  • Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

    Ramiro Garzon;Shujun Liu;Muller Fabbri;Zhongfa Liu

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

    Sarah E. M. Herman;Amber L. Gordon;Erin Hertlein;Asha Ramanunni

  • The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

    Don M. Benson;Courtney E. Bakan;Anjali Mishra;Craig C. Hofmeister

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype

    Clara D. Bloomfield;David Lawrence;John C. Byrd;Andrew Carroll

  • Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

    Jason A. Dubovsky;Kyle A. Beckwith;Gayathri Natarajan;Jennifer A. Woyach

  • CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

    Brian J. Lannutti;Sarah A. Meadows;Sarah E. M. Herman;Adam Kashishian

  • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

    John C. Byrd;Bercedis L. Peterson;Vicki A. Morrison;Kathleen Park

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

Frequent Co-Authors

Michael R. Grever
Michael R. Grever The Ohio State University
Nyla A. Heerema
Nyla A. Heerema The Ohio State University
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Jennifer R. Brown
Jennifer R. Brown Harvard University
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Steven Coutre
Steven Coutre Stanford University
Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Peter Hillmen
Peter Hillmen St James's University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t have to follow a single, traditional route. Many students choose online degrees to enter healthcare more quickly or from a non-traditional background. For example, fast track lpn programs are designed for those seeking a quicker entry into nursing, allowing students to become Licensed Practical Nurses faster than through standard pathways.

For those interested in advanced patient care, particularly in mental health, online pmhnp programs provide flexible options to become a Psychiatric Mental Health Nurse Practitioner. These programs can open doors to specialized roles and address the growing need for mental health professionals.

Not all healthcare roles involve direct patient care. Students interested in the business and leadership side of medicine may opt for an online health management degree, ideal for those aiming to manage hospitals, clinics, or other medical facilities. For a more advanced credential at a lower cost, the cheapest online mha programs offer a path to a master’s degree in health administration.

These diverse online pathways make healthcare education more accessible and adaptable to suit different goals and schedules, supporting a wide range of rewarding careers beyond traditional medical school.

Best Scientists Citing John C. Byrd

Trending Scientists